Esomeprazole for acid peptic disorders

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 655-663

  Kale Pradhan, Pramodini B ^a   Landry, Heather K ^a   Sypula, William T ^a   Mena, Rafaela ^a   Perreault, Marc M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Esomeprazole; Gastroesophageal reflux; Peptic ulcer; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; QUINIDINE; RABEPRAZOLE; WARFARIN;

ABDOMINAL PAIN; CLINICAL TRIAL; DIARRHEA; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DUODENUM ULCER; ERADICATION THERAPY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; NAUSEA; PEPTIC ULCER; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS;

EID: 0036208749     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A104     Document Type: Review

References (36)

1. Intellectual property and chirality of drugs
2. Esomeprazole: A novel proton pump inhibitor for the treatment of acid-related disorders
3. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
4. Esomeprazole magnesium
5. Optimisation of chiral separation of omeprazole and one of its metabolites on immobilized alpha-1-acid glycoprotein using chemometrics
6. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans
7. Agents for control of gastric acidity in treatment of peptic ulcers
8. Pharmacokinetics (PK) and effect on pentagastrin simulated peak output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)
9. Pharmacokinetics (PK) and dose-response relationship of esomeprazole
10. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg
11. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg
12. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg
13. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
14. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
15. Pharmacokinetics of esomeprazole in patients with liver cirrhosis
16. Pharmacokinetic study of esomeprazole in the elderly
17. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative GERD: Placebo-controlled trial of on-demand therapy for 6 months
18. Esomeprazole 20 mg maintains symptoms control in endoscopy-negative GERD: A randomized placebo-controlled trial of on-demand therapy for 6 months
19. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: A randomized controlled trial
20. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis (EE) in GERD patients
21. Esomeprazole once daily for 6 months is effective for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease systems: A randomized, double-blind, placebo-controlled study of efficacy and safety
22. Safety and efficacy of long-term treatment with esomeprazole in patients with healed erosive esophagitis (EE)
23. Esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis (EE)
24. 7-Day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (Hp) eradication in duodenal ulcer (DU) disease
25. 7-Day treatment with esomeprazole-based triple therapy eradicates H. pylori (Hp) and heals patients with duodenal ulcer (DU) disease
26. Esomeprazole based triple therapy is more effective than dual therapy for eradication of H. pylori
27. Six month safety and tolerability of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (EE)
28. Safety of long-term treatment with a new PPT, esomeprazole in GERD patents
29. Gastrointestinal drugs
30. Esomeprazole